Form 4: ARS Pharmaceuticals CFO Acquires Stock Options

Kathleen D. Scott, CFO of ARS Pharmaceuticals, acquired stock options for 176,700 shares on January 2, 2025, according to a Form 4 filing.

Summary

• Kathleen D. Scott, the Chief Financial Officer of ARS Pharmaceuticals, Inc. (SPRY), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on January 2, 2025.
• Scott acquired stock options for 176,700 shares of common stock at an exercise price of $10.71 per share.
• The options vest in 48 equal monthly installments starting January 1, 2025, and expire on January 1, 2035.
• Following the transaction, Scott directly owns derivative securities for 176,700 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard SEC filing related to stock option grants. The CFO's acquisition of options could be interpreted as a slightly positive signal, but it's a routine part of executive compensation.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by a company's officer.

Stakeholder Impact

• The acquisition of stock options by the CFO could have a minor positive impact on shareholder sentiment.

Key Dates